Endovascular Grafts for Aortic Disorders

This trial tests a special kind of endovascular graft, the Physician Modified Endovascular Graft, which surgeons customize to fit a patient's unique anatomy for treating aortic disorders. The goal is to determine if these modified grafts can be used safely and effectively. This trial may suit individuals with serious aortic issues, such as large or fast-growing aneurysms, who face high risks with traditional surgery. Participants must attend regular follow-up visits for five years to monitor the treatment's success. As an unphased trial, it provides patients with a unique opportunity to access innovative treatment options tailored to their specific needs.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that physician-modified endovascular grafts (PMEG) are generally safe for treating aortic problems. One study reported no deaths within the first 30 days or even after one year for a specific type of graft repair, indicating a strong initial safety record. However, another study found that about 7.6% of patients experienced aorta-related deaths over approximately four years.

The Physician Modified Endovascular Graft is unique because it allows surgeons to customize a commercially available graft to fit the specific anatomy of each patient with aortic disorders. Traditional treatments often rely on pre-manufactured grafts that may not perfectly match every patient's anatomy, potentially leading to less optimal outcomes. This tailored approach aims to improve the precision and effectiveness of the repair, potentially reducing complications and enhancing recovery. Researchers are excited about this treatment because it represents a personalized solution in vascular surgery, which could lead to better patient-specific outcomes.

Research has shown that custom-made endovascular grafts, known as PMEG, are highly effective in treating aortic problems. One study found that the procedure was completed as planned in 93.7% of cases, and the graft functioned well without major issues in 82.6% of cases. Another study reported that after five years, survival rates ranged from 41% to 69%, depending on the patient's other health conditions. At three years, 97.2% of patients remained alive, with most not experiencing issues like graft instability or needing additional surgeries. These findings suggest PMEG is a promising option for those requiring personalized treatment for aortic conditions. Participants in this trial will receive a Physician Modified Endovascular Graft tailored to their anatomy for surgery.¹⁵⁶⁷⁸